Cost-effectiveness of Carbapenem-resistant Enterobacteriaceae (CRE) Surveillance in Maryland
Overview
Infectious Diseases
Nursing
Public Health
Authors
Affiliations
Objective: We analyzed the efficacy, cost, and cost-effectiveness of predictive decision-support systems based on surveillance interventions to reduce the spread of carbapenem-resistant Enterobacteriaceae (CRE).
Design: We developed a computational model that included patient movement between acute-care hospitals (ACHs), long-term care facilities (LTCFs), and communities to simulate the transmission and epidemiology of CRE. A comparative cost-effectiveness analysis was conducted on several surveillance strategies to detect asymptomatic CRE colonization, which included screening in ICUs at select or all hospitals, a statewide registry, or a combination of hospital screening and a statewide registry.
Setting: We investigated 51 ACHs, 222 LTCFs, and skilled nursing facilities, and 464 ZIP codes in the state of Maryland.
Patients Or Participants: The model was informed using 2013-2016 patient-mix data from the Maryland Health Services Cost Review Commission. This model included all patients that were admitted to an ACH.
Results: On average, the implementation of a statewide CRE registry reduced annual CRE infections by 6.3% (18.8 cases). Policies of screening in select or all ICUs without a statewide registry had no significant impact on the incidence of CRE infections. Predictive algorithms, which identified any high-risk patient, reduced colonization incidence by an average of 1.2% (3.7 cases) without a registry and 7.0% (20.9 cases) with a registry. Implementation of the registry was estimated to save $572,000 statewide in averted infections per year.
Conclusions: Although hospital-level surveillance provided minimal reductions in CRE infections, regional coordination with a statewide registry of CRE patients reduced infections and was cost-effective.
Lin G, Poleon S, Hamilton A, Salvekar N, Jara M, Haghpanah F One Health. 2025; 20():100951.
PMID: 39816238 PMC: 11733049. DOI: 10.1016/j.onehlt.2024.100951.
Boutzoukas A, Mackow N, Giri A, Komarow L, Hill C, Chen L J Antimicrob Chemother. 2024; 79(11):2916-2922.
PMID: 39236214 PMC: 11531819. DOI: 10.1093/jac/dkae306.
Fanelli C, Pistidda L, Terragni P, Pasero D Antibiotics (Basel). 2024; 13(8).
PMID: 39200090 PMC: 11351734. DOI: 10.3390/antibiotics13080789.
Kuloglu T, Unuvar G, Cevahir F, Kilic A, Alp E J Intensive Med. 2024; 4(3):347-354.
PMID: 39035617 PMC: 11258511. DOI: 10.1016/j.jointm.2023.11.007.
Allel K, Hernandez-Leal M, Naylor N, Undurraga E, Abou Jaoude G, Bhandari P BMJ Glob Health. 2024; 9(2).
PMID: 38423548 PMC: 10910705. DOI: 10.1136/bmjgh-2023-013205.